LYMFOXP1

ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS

Coordinatore	FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA    more  Organization address address: AVENIDA DE PIO XII 55 city: PAMPLONA postcode: 31008 contact info Titolo: Dr. Nome: Andrew Cognome: Solomon Email: send email Telefono: 34948194700 Fax: 34948194718
Nazionalità Coordinatore	Spain [ES]
Totale costo	230˙036 €
EC contributo	230˙036 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IIF
Funding Scheme	MC-IIF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2016-05-02

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA  Organization address address: AVENIDA DE PIO XII 55 city: PAMPLONA postcode: 31008 contact info Titolo: Dr. Nome: Andrew Cognome: Solomon Email: send email Telefono: 34948194700 Fax: 34948194718	ES (PAMPLONA)	coordinator	230˙036.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that has been demonstrated to be expressed in a subset of activated B-cell type (ABC) diffuse B-cell lymphomas (DLBCLs). Strong FOXP1 expression appears to have an additive adverse role in the pathogenesis and clinical behavior of ABC-DLBCL. We believe that a better understanding of the molecular impact of FOXP1 deregulation in DLBCL will help us to improve the correct stratification of cancer patients as a prerequisite for acute diagnosis, and will allow us to propose novel pre-clinical therapeutic strategies to target the FOXP1-axis. To achieve this, we propose to characterize a collection of primary human DLBCL samples, stablished cell lines and the novel Emu-FOXP1 transgenic mouse model that has been recently generated in our lab, in an attempt to identify deregulated B-cell functional pathways, as well as sets of genetic and epigenetic events that might be 'passengers' and/or 'drivers' of lymphomagenesis. Our preliminary data has identified the B-cell mutagenic enzyme AID (activation-induced deaminase) as a FOXP1-target gene that could promote genetic and epigenetic instability in germinal-center B-cells. Consequently, we propose to explore the functional interaction of FOXP1 and AID both during normal B-cell activation and malignant B-cell transformation. By exploring functional and therapeutic strategies of targeting potential FOXP1/AID-related targets we pursue the development of translational protocols that could be used in the clinic to better diagnose patients with DLBCL and set the basis for designing future treatments and clinical trials.'